Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 14/20 | 0.67 |
| ▸ | PIM2 | Q9P1W9 | 12/20 | 0.67 |
| ▸ | PIM3 | Q86V86 | 6/20 | 0.67 |
| ▸ | CDC7 | O00311 | 9/20 | 0.52 |
| ▸ | CSNK2B | P67870 | 5/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2062868 | 1.00 | PIM1 (0.67) | PIM1PIM2PIM3CDC7CSNK2B | |
| SCHEMBL4213634 | 0.80 | PIM1 (1.00) | PIM1PIM2PIM3CDC7CSNK2B | |
| SCHEMBL2064151 | 0.77 | PIM1 (0.79) | PIM1PIM2PIM3CDC7CSNK2B | |
| SCHEMBL2062921 | 0.76 | RAB9A (0.43) | PIM1PIM2PIM3 | |
| SCHEMBL14343624 | 0.74 | PIM1 (0.56) | PIM1PIM2PIM3CDC7CSNK2B | |
| SCHEMBL14343458 | 0.74 | PIM1 (0.56) | PIM1PIM2PIM3CDC7CSNK2B | |
| SCHEMBL4206452 | 0.73 | PIM1 (0.56) | PIM1PIM2PIM3CDC7CSNK2B | |
| SCHEMBL4207265 | 0.73 | PIM1 (1.00) | PIM1PIM2PIM3CDC7 | |
| SCHEMBL4212115 | 0.73 | PIM1 (1.00) | PIM1PIM2PIM3CDC7 | |
| SCHEMBL4205544 | 0.73 | PIM1 (1.00) | PIM1PIM2PIM3CDC7CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | claimed |
| US-8148384-B2 | 8-bromo-2-[(3-hydroxyphenylamino)methyl]-3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-one; ischemia reperfusion injury, inflammatory disease, retroviral infections, ischemia reperfusion injury, myocardial infarction | ABBOTT LABORATORIES (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080161559-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161578-A1 | 8-bromo-2-[(3-hydroxyphenylamino)methyl]-3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-one; increasing cell death of cancer cells, limiting tumor growth, decreasing metastasis, and prolonging the survival of tumor-bearing animals | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161578-A1 | 8-bromo-2-[(3-hydroxyphenylamino)methyl]-3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-one; increasing cell death of cancer cells, limiting tumor growth, decreasing metastasis, and prolonging the survival of tumor-bearing animals | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885PIM3 3/4885 |
| US-20080161559-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | PIM1, PIM3, PIM2 | PIM1 1/4885PIM2 3/4885PIM3 2/4885 |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | PIM1, PIM3, PIM2 | PIM1 1/4885PIM2 3/4885PIM3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.